Emergence of spontaneous bacterial peritonitis due to enterococci - Risk factors and outcome in a 12-year retrospective study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 10, 2012, Pages 1199-1208

  Reuken, P A ^a   Pletz, M W ^a   Baier, M ^a   Pfister, W ^a   Stallmach, A ^a   Bruns, T ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; CIPROFLOXACIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; ASCITES FLUID; ASCITES FLUID ANALYSIS; ASCITES FLUID CULTURE; BACTERIAL PERITONITIS; BACTERIUM ISOLATION; DIGESTIVE TRACT ENDOSCOPY; DRUG USE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FEMALE; GERMANY; HOSPITAL INFECTION; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS BACTERIAL PERITONITIS; SURVIVAL RATE; UNIVARIATE ANALYSIS;

AGED; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; ASCITIC FLUID; CEPHALOSPORINS; CIPROFLOXACIN; ENTEROCOCCUS; FEMALE; GERMANY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PERITONITIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859915099     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05076.x     Document Type: Article

References (45)

1. Nousbaum J-B, Cadranel J-F, Nahon P, et al,. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 2007; 45: 1275-81. (Pubitemid 46775791)
2. Bruns T, Peter J, Reuken PA, et al,. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int 2012; 32: 223-30.
3. Evans LT, Kim WR, Poterucha JJ, Kamath PS,. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37: 897-901. (Pubitemid 36397402)
4. Rimola A, García-Tsao G, Navasa M, et al,. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32: 142-53. (Pubitemid 30039459)
5. Fernández J, Navasa M, Gõmez J, et al,. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8. (Pubitemid 34032554)
6. Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ,. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int 2005; 25: 57-61. (Pubitemid 40298245)
7. Park YH, Lee HC, Song HG, et al,. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003; 18: 927-33. (Pubitemid 37056172)
8. Runyon BA,. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.
9. Ginès P, Angeli P, Lenz K, et al,. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
10. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G,. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066-70. (Pubitemid 28215464)
11. Bert F, Andreu M, Durand F, et al,. Nosocomial and community-acquired spontaneous bacterial peritonitis: comparative microbiology and therapeutic implications. Eur J Clin Microbiol Infect Dis 2003; 22: 10-5. (Pubitemid 36286687)
12. Cheong HS, Kang C-I, Lee JA, et al,. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009; 48: 1230-6.
13. Murray BE,. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3: 46-65. (Pubitemid 20078774)
14. Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W,. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009; 37: 2-8.
15. Angeloni S, Leboffe C, Parente A, et al,. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol 2008; 14: 2757-62.
16. National Institute of Public Health and the Environment. EARSS Annual Report 2008. Available at:. Accessed November 30, 2011.
17. Runyon BA, Hoefs JC, Canawati HN,. Polymicrobial bacterascites: a unique entity in the spectrum of infected ascitic fluid. Arch Intern Med 1986; 146: 2173-5. (Pubitemid 17189091)
18. Runyon BA,. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 1990; 12: 710-5. (Pubitemid 20349255)
19. Such J, Guarner C, Runyon B,. Spontaneous bacterial peritonitis in cirrhosis. In:, Ginès VP, Arroyo V, Rodes J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Massachusetts: Blackwell Publishing Ltd, 2005; 422-33.
20. Navasa M, Rodés J,. Antibiotic therapy of spontaneous bacterial peritonitis. In:, Conn HO, Rodés J, Navasa M, eds. Spontaneous Bacterial Peritonitis: The Disease: Pathogenesis, and Treatment. New York: Marcel Dekker, Inc., 2000; 189-200.
21. Heo J, Seo YS, Yim HJ, et al,. Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver 2009; 3: 197-204.
22. Gou Y-Z, Liu B, Pan L, Yu H-T, Wang J-P, Wang D-C,. Pathogens of spontaneous bacterial peritonitis change in northern China. Saudi Med J 2010; 31: 1152-6.
23. Bert F, Noussair L, Lambert-Zechovsky N, Valla D,. Viridans group Streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Eur J Gastroenterol Hepatol 2005; 17: 929-33. (Pubitemid 41192131)
24. Singh N, Wagener MM, Gayowski T,. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003; 9: 531-7. (Pubitemid 36833798)
25. Campillo B, Richardet J-P, Kheo T, Dupeyron C,. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002; 35: 1-10. (Pubitemid 34666853)
26. Barrall DT, Kenney PR, Slotman GJ, Burchard KW,. Enterococcal bacteremia in surgical patients. Arch Surg 1985; 120: 57-63. (Pubitemid 15001218)
27. Pallares R, Pujol M, Peña C, Ariza J, Martin R, Gudiol F,. Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia. A matched case-control study. Arch Intern Med 1993; 153: 1581-6. (Pubitemid 23205857)
28. Noskin GA, Peterson LR, Warren JR,. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20: 296-301.
29. Patel R, Badley AD, Larson-Keller J, et al,. Relevance and risk factors of Enterococcal bacteremia following liver transplantation. Transplantation 1996; 61: 1192-7. (Pubitemid 26134769)
30. Lee J-H, Yoon J-H, Kim BH, et al,. Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Clin Microbiol Infect Dis 2009; 28: 21-6.
31. Yip T, Tse K-C, Ng F, et al,. Clinical course and outcomes of single-organism Enterococcus peritonitis in peritoneal dialysis patients. Perit Dial Int 2011; 31: 522-8.
32. Seguin P, Brianchon C, Launey Y, et al,. Are enterococci playing a role in postoperative peritonitis in critically ill patients? Eur J Clin Microbiol Infect Dis 2011 [Epub ahead of print].
33. Harbarth S, Uckay I,. Are there patients with peritonitis who require empiric therapy for Enterococcus? Eur J Clin Microbiol Infect Dis 2004; 23: 73-7. (Pubitemid 38392132)
34. Onderdonk AB, Bartlett JG, Louie T, Sullivan-Seigler N, Gorbach SL,. Microbial synergy in experimental intra-abdominal abscess. Infect Immun 1976; 13: 22-6.
35. Montravers P, Mohler J, Saint Julien L, Carbon C,. Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats. Infect Immun 1997; 65: 144-9. (Pubitemid 27008915)
36. Van Ruler O, Kiewiet JJS, Van Ketel RJ, Boermeester MA,. Initial microbial spectrum in severe secondary peritonitis and relevance for treatment. Eur J Clin Microbiol Infect Dis 2012; 31: 671-82.
37. Bérenger R, Bourdon N, Auzou M, Leclercq R, Cattoir V,. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Med Mal Infect 2011; 41: 405-9.
38. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE,. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009; 18: 921-44.
39. Arias CA, Contreras GA, Murray BE,. Management of multidrug-resistant Enterococcal infections. Clin Microbiol Infect 2010; 16: 555-62.
40. Chen Z, Wu J, Zhang Y, et al,. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 2010; 10: 217.
41. Oliva ME, Rekha A, Yellin A, et al,. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88.
42. Freire AT, Melnyk V, Kim MJ, et al,. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-51.
43. Welte T, Pletz MW,. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010; 36: 391-400.
44. European Medicines Agency. Questions and answers on the review of Tygacil (tigecycline)-Outcome of a renewal procedure 2011. Available at:. Accessed December 11, 2011.
45. Sandiumenge A, Diaz E, Bodí M, Rello J,. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003; 29: 876-83. (Pubitemid 36789779)